Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: Exploring a new frontier

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose of review Integrating targeted therapies against the epidermal growth factor receptor (EGFR) and angiogenesis pathways into standard treatment paradigms for advanced nonsmall cell lung cancer (NSCLC) have been successful, but not yet curative. Two treatment strategies, in development, seem particularly appealing for further study: insulin-like growth factor receptor (IGF-1R) and histone deacetylase (HDAC) inhibition. Several lines of evidence suggest that these novel approaches may play a relevant role in the future treatment of NSCLC. Recent findings Preliminary results of a phase II trial combining an anti-IGF-1 R monoclonal antibody with platinum-based chemotherapy in untreated NSCLC patients have shown an encouraging response rate, particularly in those with squamous cell carcinoma, where IGFR expression is typically high. Recent data also support the clinical development of HDAC inhibitors as a strategy to counter epigenetic gene silencing and transcriptional repression of key anticancer genes. Moreover, research efforts are focusing on identifying predictive markers to appropriately select patients for maximal therapeutic benefit. Summary Here, we briefly review data regarding anti-EGFR and antiangiogenesis agents before discussing the potential roles for IGF-1R and HDAC inhibitors in NSCLC management, and the need for optimizing treatment by seeking a more personalized approach to care.

Original languageEnglish (US)
Pages (from-to)116-123
Number of pages8
JournalCurrent Opinion in Oncology
Volume21
Issue number2
DOIs
StatePublished - Mar 2009

Fingerprint

Growth Factor Receptors
Non-Small Cell Lung Carcinoma
Histone Deacetylase Inhibitors
Epidermal Growth Factor Receptor
Therapeutics
Somatomedin Receptors
Histone Deacetylases
Gene Silencing
Platinum
Insulin-Like Growth Factor I
Epigenomics
Squamous Cell Carcinoma
Monoclonal Antibodies
Drug Therapy
Research
Genes

Keywords

  • Epigenetics
  • Histone deacetylase inhibitors
  • Insulin-like growth factor
  • New strategies
  • Nonsmall cell lung cancer
  • Personalized medicine
  • Targeted therapies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{40c8110da76d4e789ef1b85eae46a214,
title = "Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: Exploring a new frontier",
abstract = "Purpose of review Integrating targeted therapies against the epidermal growth factor receptor (EGFR) and angiogenesis pathways into standard treatment paradigms for advanced nonsmall cell lung cancer (NSCLC) have been successful, but not yet curative. Two treatment strategies, in development, seem particularly appealing for further study: insulin-like growth factor receptor (IGF-1R) and histone deacetylase (HDAC) inhibition. Several lines of evidence suggest that these novel approaches may play a relevant role in the future treatment of NSCLC. Recent findings Preliminary results of a phase II trial combining an anti-IGF-1 R monoclonal antibody with platinum-based chemotherapy in untreated NSCLC patients have shown an encouraging response rate, particularly in those with squamous cell carcinoma, where IGFR expression is typically high. Recent data also support the clinical development of HDAC inhibitors as a strategy to counter epigenetic gene silencing and transcriptional repression of key anticancer genes. Moreover, research efforts are focusing on identifying predictive markers to appropriately select patients for maximal therapeutic benefit. Summary Here, we briefly review data regarding anti-EGFR and antiangiogenesis agents before discussing the potential roles for IGF-1R and HDAC inhibitors in NSCLC management, and the need for optimizing treatment by seeking a more personalized approach to care.",
keywords = "Epigenetics, Histone deacetylase inhibitors, Insulin-like growth factor, New strategies, Nonsmall cell lung cancer, Personalized medicine, Targeted therapies",
author = "Randeep Sangha and Lara, {Primo N} and Philip Mack and Gandara, {David R}",
year = "2009",
month = "3",
doi = "10.1097/CCO.0b013e3283210489",
language = "English (US)",
volume = "21",
pages = "116--123",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer

T2 - Exploring a new frontier

AU - Sangha, Randeep

AU - Lara, Primo N

AU - Mack, Philip

AU - Gandara, David R

PY - 2009/3

Y1 - 2009/3

N2 - Purpose of review Integrating targeted therapies against the epidermal growth factor receptor (EGFR) and angiogenesis pathways into standard treatment paradigms for advanced nonsmall cell lung cancer (NSCLC) have been successful, but not yet curative. Two treatment strategies, in development, seem particularly appealing for further study: insulin-like growth factor receptor (IGF-1R) and histone deacetylase (HDAC) inhibition. Several lines of evidence suggest that these novel approaches may play a relevant role in the future treatment of NSCLC. Recent findings Preliminary results of a phase II trial combining an anti-IGF-1 R monoclonal antibody with platinum-based chemotherapy in untreated NSCLC patients have shown an encouraging response rate, particularly in those with squamous cell carcinoma, where IGFR expression is typically high. Recent data also support the clinical development of HDAC inhibitors as a strategy to counter epigenetic gene silencing and transcriptional repression of key anticancer genes. Moreover, research efforts are focusing on identifying predictive markers to appropriately select patients for maximal therapeutic benefit. Summary Here, we briefly review data regarding anti-EGFR and antiangiogenesis agents before discussing the potential roles for IGF-1R and HDAC inhibitors in NSCLC management, and the need for optimizing treatment by seeking a more personalized approach to care.

AB - Purpose of review Integrating targeted therapies against the epidermal growth factor receptor (EGFR) and angiogenesis pathways into standard treatment paradigms for advanced nonsmall cell lung cancer (NSCLC) have been successful, but not yet curative. Two treatment strategies, in development, seem particularly appealing for further study: insulin-like growth factor receptor (IGF-1R) and histone deacetylase (HDAC) inhibition. Several lines of evidence suggest that these novel approaches may play a relevant role in the future treatment of NSCLC. Recent findings Preliminary results of a phase II trial combining an anti-IGF-1 R monoclonal antibody with platinum-based chemotherapy in untreated NSCLC patients have shown an encouraging response rate, particularly in those with squamous cell carcinoma, where IGFR expression is typically high. Recent data also support the clinical development of HDAC inhibitors as a strategy to counter epigenetic gene silencing and transcriptional repression of key anticancer genes. Moreover, research efforts are focusing on identifying predictive markers to appropriately select patients for maximal therapeutic benefit. Summary Here, we briefly review data regarding anti-EGFR and antiangiogenesis agents before discussing the potential roles for IGF-1R and HDAC inhibitors in NSCLC management, and the need for optimizing treatment by seeking a more personalized approach to care.

KW - Epigenetics

KW - Histone deacetylase inhibitors

KW - Insulin-like growth factor

KW - New strategies

KW - Nonsmall cell lung cancer

KW - Personalized medicine

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=62349122171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62349122171&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e3283210489

DO - 10.1097/CCO.0b013e3283210489

M3 - Article

C2 - 19532012

AN - SCOPUS:62349122171

VL - 21

SP - 116

EP - 123

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 2

ER -